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Abstract
Biological markers for risk stratification of chronic GvHD (cGvHD) could improve the care of 
patients undergoing allogeneic hematopoietic stem cell transplantation. Increased plasma levels of 
B-cell activating factor (BAFF), chemokine (C-X-C motif) ligand 9 (CXCL9) and elafin have been 
associated with the diagnosis, but not with outcome in patients with cGvHD. We evaluated the 
association between levels of these soluble proteins, measured by ELISA at the time of cGvHD 
diagnosis and before the initiation of therapy, with non-relapse-mortality (NRM). Based on the 
log-transformed values, factor levels were divided into tertiles defined respectively as low, 
intermediate, and high levels. On univariable analysis, BAFF levels were significantly associated 
with NRM, whereas CXCL9 and elafin levels were not. Both low (≤2.3 ng/mL, hazard ratio (HR)= 
5.8, P= 0.03) and high (>.7 ng/mL, HR=5.4, P =0.03) BAFF levels were associated with a 
significantly higher NRM compared with intermediate BAFF level. The significant effect of high 
or low BAFF levels persisted in multivariable analysis. A subset of cGvHD patients had 
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persistently low BAFF levels. In conclusion, our data show that BAFF levels at the time of cGvHD 
diagnosis are associated with NRM, and also are potentially useful for risk stratification. These 
results warrant confirmation in larger studies.
Introduction
Chronic GvHD (cGvHD) remains the main long-term limitation to successful allogeneic 
hematopoietic stem cell transplantation (HSCT).1–3 The signs and symptoms of cGvHD are 
often insidious. Thus, diagnosis and treatment typically occur after clinical manifestations 
are advanced. In addition, management of cGvHD may be suboptimal after discharge from 
the transplant center as patients are often followed by local oncologists unfamiliar with the 
clinical features of cGvHD.4 Development of a much needed diagnostic and severity scoring 
system based on clinical manifestations of cGvHD is challenging because of the complex 
and pleomorphic nature of the disease.5,6 In this context, validation of biological markers 
that would facilitate risk stratification and a more personalized approach to the management 
of cGvHD has the potential to improve outcomes.1,6
A number of potentially viable biomarkers in cGvHD have been identified through 
proteomics. Of these, soluble B-cell activating factor (BAFF), chemokine (C-X-C motif) 
ligand 9 (CXCL9) and elafin have been associated with the diagnosis of cGvHD7–12 but 
their potential association with outcome remains unknown. In this study, we evaluate the 
association of these three soluble factors with non-relapse mortality (NRM) in a cohort of 
newly diagnosed cGvHD patients. We focused our assessment on the time of cGvHD 
diagnosis, before the initiation of systemic therapy for cGvHD, when clinical manifestations 
are potentially reversible and risk-adapted treatment is most likely to be successful.
Patients and Methods
Study population
From January 2007 through December 2010, 341 consecutive adult patients underwent their 
first allogeneic HSCT at the University of Michigan. Of these, a total of 287 survived 
beyond post-HSCT day (D100); 158 patients who developed cGvHD and had not been 
diagnosed with progression of their underlying malignancy before the onset of cGvHD were 
included in this analysis. All patients provided informed consent to participate in an 
institutional review board-approved, long-term follow-up study. Patient cGvHD data were 
prospectively collected into the University of Michigan Bone Marrow Transplant Program 
database.
Assessment of cGvHD and additional risk factors for NRM
Clinical cGvHD data were adjudicated by two clinicians with expertise in the field (CLK 
and DRC), and diagnosis and scoring were based on National Institutes of Health (NIH) 
Consensus Criteria.5 Lung score calculation was based on results of pulmonary function 
tests performed within 4 weeks of the diagnosis of cGvHD per published 
recommendations.13 The date of cGvHD diagnosis was defined as the time when NIH 
Consensus Criteria were first reached.
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Previously reported risk factors for NRM after HSCT were examined.14-18 Karnofsky 
Performance Status (KPS)19 was assessed as >70 or ≤70%. Acute GvHD was scored by 
modified Glucksberg criteria.20
Measurement of potential protein biomarkers
ELISA was used to determine plasma concentrations of BAFF, CXCL9 and elafin as 
previously described.9 Plasma samples were collected at the time of cGvHD diagnosis 
before the initiation of treatment for cGvHD and at 3 months interval thereafter. BAFF, 
CXCL9 and elafin levels were available in 112 (71%), 110 (70%) and 109 (69%) patients, 
respectively. All three protein levels were available for 105 of the 158 patients.
Statistical approach
NRM was defined as death because of any cause not related to progression or persistence of 
the underlying malignancy. NRM, overall survival (OS), progression-free survival (PFS) and 
progression of malignancy after cGvHD diagnosis were assessed by landmark analysis 
starting on the day of diagnosis of cGvHD. According to the inclusion criteria, none of the 
patients had experienced progression of the underlying malignancy before the onset of 
cGvHD. Therefore, in this study all reference to ‘progression of malignancy’ pertains to 
progression occurring after cGvHD diagnosis. Actuarial OS and PFS were estimated by the 
Kaplan-Meier method. The cumulative incidence method accounting for competing risks21 
was used to estimate the incidence of NRM (considering progression of the underlying 
malignancy or death with persistent malignancy as competing risks), and the incidence of 
progression of the underlying malignancy (considering NRM as a competing risk).
We evaluated the association between NRM and each of the plasma factors using Cox 
proportional hazards regression analysis on univariable and multivariable analysis. NRM-
specific hazard ratios (HRs) were generated accounting for progression of the underlying 
malignancy or death with persistent malignancy as they occurred after cGvHD 
diagnosis.22,23 Each plasma factor was initially evaluated in two separate Cox models in 
which the log-transformed values were divided into quartiles or into tertiles. The goodness-
of-fit test (based on the Cox-Snell residuals) confirmed the superiority of the Cox model 
evaluating plasma values in tertiles. Therefore, all results pertaining to plasma factors were 
presented based on the tertile classification. The first, second and third tertiles were defined 
as low, intermediate and high levels, respectively.
To identify potential confounding factors in the association between plasma factors and 
NRM, we assessed patient sociodemographic, transplantation and GvHD-related factors as 
predictors of NRM. Patient, transplantation or cGvHD factors that were associated with 
NRM at the 0.003 (P-value adjusted based on Bonferroni correction to account for multiple 
comparisons) level on univariable analysis were considered in multivariable analysis. First-
degree interaction effects were tested and were not found to be significant. Categorical 
variables were compared using the χ2 and Fisher's exact tests and continuous variables were 
compared using the Wilcoxon rank-sum rest. Logistic regression analysis was used to assess 
the relationship between BAFF levels and patient sociodemographic, transplantation and 
cGvHD characteristics. The Wilcoxon matched-pairs signed rank test was used to compare 
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serial BAFF values. Unless otherwise noted, statistical significance was defined at the 0.05 
level. Statistical analyses were performed primarily with the STATA software, version 11.0 
(College Station, TX, USA).
Results
Chronic GvHD characteristics and potential causes of NRM
Chronic GvHD was diagnosed at a median of 189 days post HSCT (range 37-806, 
interquartiles 132-273). Twenty-one (13%) patients had early-onset cGvHD (before D100), 
including one case with biopsy-proven bronchiolitis obliterans syndrome. Organ and overall 
severity at the time of cGvHD onset are presented in Table 1. The baseline demographic, 
disease and transplant characteristics of the study cohort are described in Supplementary 
Table S1. No patient received antithymocyte globulin as part of the pre-HSCT regimen. As 
our cohort comprised patients identified at the time of first diagnosis of cGvHD, no 
treatments directed at cGvHD had been started yet. In this study, we did not capture 
therapies received before or after the day of blood draw when cGvHD was first diagnosed. 
We only captured the immunosuppressive therapy that patients were receiving on the day of 
blood draw when cGvHD was first diagnosed. Such therapy was related to GvHD 
prophylaxis or prior treatment of aGvHD. Immunosuppressive agents received on the day of 
diagnosis of cGvHD are summarized in Supplementary Table S1. Twenty-six patients (16%) 
were receiving a steroid, all but 2 (1%) at a dose of ≤ 0.5 mg/kg. Among the surviving 
patients, the median follow-up time from cGvHD diagnosis was 24 months (range 3–54). At 
the time of last follow-up, OS was 63% (95% confidence interval (CI) 51–73%), PFS 58% 
(95% CI 46–68%) and NRM 27% (95% CI 18–39). The causes of the 30 deaths in the 
cGvHD patient study cohort (N = 158) are listed in Supplementary Table S2.
Plasma factors as potential predictors of NRM
At the time of cGvHD diagnosis, median BAFF level was 3.6 ng/mL (range 0–19.4), median 
CXCL9 was 20 ng/mL (range 0–171) and median elafin was 8.8 ng/mL (range 1.5–36.5). 
The linear correlations among the three plasma factors are shown in Supplementary Table 
S3. Plasma BAFF levels were positively correlated with CXCL9 (r = 0.42, P<0.01), but not 
with elafin (r = 0.18, P = 0.07) levels.
On univariable analysis, BAFF levels at the time of cGvHD diagnosis were associated with 
NRM (Figure 1a), whereas CXCL9 (Figure 1b) and elafin (Figure 1c) levels were not (Table 
2). NRM was significantly associated with either low or high BAFF level. Specifically, the 
4-year cumulative incidence of NRM was 54% in the high BAFF level group and 30% in the 
low BAFF level group. In contrast, it was 11% in the intermediate BAFF level group (Figure 
1a, P = 0.02). The NRM rates in the high and low BAFF level groups were comparable and 
not significantly different (HR = 1.0, P = 0.9).
The incidence of malignancy progression after cGvHD diagnosis was comparable across the 
three BAFF levels (P = 0.7) with a 4-year cumulative incidence of 22% (95% CI 10–46), 
20% (95% CI 9–42) and 14% (95% CI 5–35) in the low, intermediate and high BAFF 
groups, respectively (Supplementary Figure S1a). Thus, the lower rate of NRM in the 
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intermediate BAFF group was not attributable to a higher rate of malignancy progression in 
this group of patients. The 4-year actuarial PFS in the low, intermediate and high BAFF 
groups was 25% (95% CI 2–61), 69% (95% CI 43–75) and 56% (35–72), respectively 
(Supplementary Figure S1b).
Patient, transplant and cGvHD-related characteristics did not differ between the subset of 
patients who were (n= 112) or were not (n =46) evaluable for BAFF assessment (data not 
shown) except for a higher prevalence (26% vs 11%, P=0.03) of progressive-onset cGvHD 
and a shorter time interval between transplantation and cGvHD diagnosis (median 167 vs 
274 days, P<0.001) in the evaluable subset. These differences are unlikely to have biased our 
findings on the association between BAFF levels and NRM as neither one of these factors 
was associated with NRM (Supplementary Table S5) or with BAFF levels (Supplementary 
Table S6) in this patient population. Consistent with our data, a history of acute GvHD10 and 
time to cGvHD onset12 did not affect BAFF levels in independent patient cohorts. 
Importantly, NRM (HR = 0.96, P = 0.9), OS (HR = 1.2, P = 0.6) and PFS (HR = 1.3, P = 
0.4) rates did not differ between patients who were or were not evaluable for BAFF 
assessment.
Impact of patient and transplantation characteristics on NRM and BAFF levels
In order to identify potential confounding factors in the association between BAFF levels 
and NRM, we evaluated patient, transplantation and GvHD-related characteristics in relation 
to NRM in the subset of patients (N=112) who were evaluable for BAFF assessment 
(Supplementary Tables S4 and S5). Our analysis revealed that KPS ≤ 70% (HR = 4.3, P = 
0.001), and a history of severe (grades III–IV) aGvHD (HR = 5.5, P<0.001) were the only 
significant predictors of NRM. No other patient, transplant or GvHD characteristic 
examined was significantly associated with NRM. The results remained consistent when the 
univariate analysis was performed in the overall study cohort (N = 158). Multivariate 
analysis showed that low (HR = 8.5, P = 0.0009) and high (HR = 5.6, P = 0.03) BAFF levels 
remained significantly associated with NRM after adjustment for KPS ≤ 70% and a history 
of severe aGvHD (Table 3).
When we assessed the impact of patient and transplantation characteristics on BAFF levels, 
we found no significant association between low or high BAFF levels and patient age or 
gender, disease status at transplantation, intensity of conditioning regimen, donor type, 
GvHD prophylaxis regimen, a history of aGvHD, KPS, steroid therapy, platelet count and 
eosinophil count at the time of cGvHD diagnosis (Supplementary Table S6).These findings 
need to be interpreted with caution and validated in independent cohorts because our study 
was not powered for a systematic assessment of predictors of BAFF levels.
Influence of cGvHD characteristics on BAFF level
We considered whether cGvHD organ involvement, including skin, mouth, gut, liver, lung 
and eyes, was associated with BAFF levels. Of these, only skin involvement was 
significantly associated with BAFF levels (Figure 2). BAFF levels were significantly lower 
in patients with skin cGvHD than in patients without skin involvement (median 2.5 vs 5 
ng/mL, P = 0.04), and patients with skin cGvHD were significantly more likely to have low 
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BAFF levels than patients without skin involvement (46% vs 20%, P=0.003). None of the 
other organs was individually associated with BAFF levels. Duration from transplantation to 
cGvHD diagnosis, cGvHD type and global NIH severity score at onset were not 
significantly associated with BAFF levels in this patient population.
Longitudinal assessment of BAFF before and after cGvHD onset
Finally, to determine whether high or low BAFF levels occur before cGvHD diagnosis, we 
examined BAFF levels before and serially after diagnosis of cGvHD. Among the 112 
patients with samples available for BAFF measurement at the time of cGvHD diagnosis, 
baseline (measured at a median of 56 days (range 23–96 before the diagnosis of cGvHD, 
and at a median of 98 days post HSCT) BAFF level was obtainable for 39 (35%) patients. 
Baseline BAFF values were significantly lower (median 0.7 ng/mL, range 0.16–6, P=0.01) 
for patients who at the time of cGvHD diagnosis had a low BAFF level (n = 21) than for 
those who at the time of cGvHD diagnosis had an intermediate (n =8, median 1.7 ng/mL, 
range 0.35–16) or a high (n=10, median 1.98 ng/mL, range 0.9–5.8) BAFF level (Figure 3). 
BAFF levels seem to have spiked before cGvHD diagnosis for patients with intermediate or 
high BAFF levels at cGvHD onset. In contrast, for patients with a low BAFF level at cGvHD 
diagnosis, BAFF values remained at ∼1 ng/mL before, at the time of and after cGvHD 
diagnosis. We were unable to determine whether persistently low levels of BAFF related to 
prior high-dose steroid administration because these data were not captured.
Discussion
The ability to predict NRM could guide therapeutic decisions in the management of cGvHD 
patients. The current study is the first one to demonstrate that soluble BAFF concentrations 
predict NRM in patients with cGvHD. A major strength of our study design is that BAFF 
concentrations were assessed at the time of diagnosis of cGvHD and before initiation of 
therapy. Validation of our findings in independent patient cohorts will be necessary before 
the risk stratification we are proposing based on BAFF concentrations could be used to 
guide therapy at the time of onset of cGvHD.
Our definition of BAFF levels was statistically derived; however, the ranges of BAFF 
concentrations in the low, intermediate and high BAFF groups respectively corresponded to 
BAFF concentrations reported in non-transplanted healthy individuals (median 1 ng/
mL)10,12,24–26, in patients with inactive cGvHD (median 5.7 ng/mL)12 and in patients with 
active cGvHD (median 9.9 ng/mL)12. Of note, intermediate BAFF levels at the time of 
cGvHD diagnosis (median: 3.6 ng/mL, range 2.4–5.7 ng/mL) identified a group of patients 
at low risk for NRM. In contrast, BAFF concentrations on either side of the intermediate 
range were significantly associated with a high risk of NRM. We could not evaluate whether 
the association between BAFF levels and NRM is limited to patients with cGvHD because 
this study lacked a control group of transplant recipients who did not develop cGvHD. 
Hence, our findings apply to newly diagnosed cGvHD patients.
A significant association between elevated soluble BAFF levels and the diagnosis of cGvHD 
has consistently been shown in several patient cohorts,9,10,12,27,28 and prior studies have 
shown an association between BAFF levels and cGvHD treatment response.27,29 Consistent 
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with findings in prior studies,10 BAFF levels in our current study were more likely to be 
elevated before the diagnosis of cGvHD in patients who presented with intermediate or high 
BAFF levels; and we have now linked persistently elevated BAFF levels to NRM in newly 
diagnosed cGvHD patients. Our finding that BAFF, but not two other cGvHD candidate 
biomarkers for cGvHD examined in this study (CXCL9 and elafin), was significantly 
associated with NRM further supports a role for BAFF in cGvHD pathobiology.28,30,31 This 
finding is also consistent with work by others revealing that BAFF polymorphisms 
potentially associate with GvHD outcome after HSCT.32 In contrast to patients who 
presented with intermediate or high BAFF levels, patients who presented with low BAFF 
levels at the onset of cGvHD tended to have persistently low levels before and after the 
diagnosis of cGvHD. This finding suggests that some patients with cGvHD have disease 
unaffected by BAFF.33 Others have reported low BAFF levels in other inflammatory states 
such as inflammatory skin diseases including atopic dermatitis,25,34 and recent data by Vital 
et al.35 support a BAFF-independent inflammation pathway in the development of cutaneous 
systemic lupus erythematosus. In line with these data suggesting a BAFF-independent 
pathway in skin disorders, our data revealed that patients with low BAFF levels were 
significantly more likely to have skin cGvHD. The reported association between low BAFF 
and IgE mediated or related diseases26 further support the need to further study the potential 
mechanism for development of organ-specific cGvHD manifestations in the context of low 
BAFF levels. Consistent with prior studies,10 we did not detect significant associations 
between BAFF levels and other cGvHD, patient or transplantation characteristics.
The reason for the association between low BAFF levels and poor cGvHD outcome remains 
to be determined. Treatment with high-dose steroids was associated with lower BAFF levels 
in one study10 but not in others.3,8 In our evaluation, only a small fraction of the patient 
population was receiving steroid therapy at the time of cGvHD diagnosis, and we did not 
find an association of high-dose steroid use at the time of cGvHD diagnosis and BAFF level. 
This, however, does not preclude the possibility that patients with low BAFF levels had 
received prior steroid therapy for treatment of aGvHD. We were not able to verify this 
possibility in the current study because we did not capture the cumulative dose of steroids 
received before the diagnosis of cGvHD. High concentration of BAFF per B cell (BAFF/B-
cell ratio) and promotion of activated B cells is found in patients with active cGvHD.36,37 In 
contrast, supranormal B-cell numbers are associated with low BAFF levels. Herein, we were 
unable to directly assess whether low BAFF was related to high B-cell numbers because we 
did not evaluate B-cell reconstitution. Our data suggest attention is warranted in future 
studies to patients with low BAFF levels and cGvHD incidence and outcomes.
Because of its retrospective nature, this study had important limitations including the lack of 
data on the treatment of acute and chronic GvHD, and the lack of a control group of healthy 
controls and transplant recipients who did not develop cGvHD. However, in spite of these 
limitations and in light of prior data showing an association between BAFF levels and 
cGvHD treatment response,27,29 our findings suggest that BAFF may aid in prognostication 
for cGvHD patients and merit validation in future studies.
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Figure 1. 
Cumulative incidence curves of non-relapse mortality (NRM) after cGvHD diagnosis 
according to plasma concentrations at the time of cGvHD diagnosis of BAFF (a), CXCL9 
(b) or elafin (c) in tertile groups. Concentration of each plasma factor measured by ELISA at 
the time of cGvHD diagnosis after allogeneic HSCT was divided into tertiles based on the 
log-transformed values. The first, second and third tertiles were defined as low, intermediate 
and high levels, respectively (as described in Statistical approach). The cumulative incidence 
of NRM curves are shown for cGvHD patients with high (gray line), intermediate (dotted 
black line) and low (bold black line) soluble factor levels as defined in Table 2.
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Figure 2. 
Serum BAFF levels vary according to skin involvement in patients with cGvHD. 
Concentration of serum BAFF measured by ELISA at the time of cGvHD diagnosis after 
allogeneic HSCT in 58 patients with and 54 patients without skin involvement at the time of 
cGvHD diagnosis. Data are illustrated as box-and-whisker plots with the whiskers indicating 
the 90th and 10th percentiles. Lines within box plots indicate the median BAFF 
concentration for each group.
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Figure 3. 
Changes in plasma BAFF concentration over time in patients who had low, intermediate or 
high BAFF level at the time of cGvHD diagnosis. Concentrations of plasma BAFF measured 
by ELISA at the time of cGvHD diagnosis after allogeneic HSCT were divided into tertiles 
based on the distribution of the log-transformed values. The first, second and third tertiles 
were defined as low, intermediate and high levels, respectively (as described in Statistical 
approach). Serial ELISA results of plasma BAFF concentrations from cGvHD patients with 
high BAFF tertile (gray line), intermediate BAFF tertile (dotted black line) and low BAFF 
tertile (bold black line) are shown with the numbers (n) of samples available at each time 
point. P-values were derived based on the Wilcoxon matched-pairs signed rank test 
comparing BAFF values measured before, at the time of and after the diagnosis of cGvHD.
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Table 1
GvHD characteristics at the time of cGvHD diagnosis of the study (N=158) cohort and of 
the subset of patients (N=112) evaluable for BAFF assessment
Characteristics N=158 (%) N = 112 (%)
Days from transplant to cGvHD diagnosis, median (interquartiles) 189 (132,273) 167 (126,207)
History of grade 34/40/20 21%/ 29/24 26%/21%
I/II/III–IV aGvHD 25%/13% /11 /10%
cGvHD onset presentation
 De novo 64 41% 48 43%
 Quiescent 60 38% 35 31%
 Progressive 34 21% 29 26%
Global NIH-CC severity
 Mild 23 15% 16 14%
 Moderate 79 50% 54 48%
 Severe 56 35% 42 37%
Organ involvement according to NIH-CC
 Skin
  None 78 49% 54 48%
  Mild 32 20% 26 23%
  Moderate 26 16% 16 14%
  Severe 22 14% 16 14%
 Mouth
  None 25 16% 12 11%
  Mild 113 71% 85 76%
  Moderate 18 11% 14 12%
  Severe 2 1% 1 1%
 Eye
  None 111 70% 80 71%
  Mild 35 22% 25 22%
  Moderate 11 7% 6 5%
  Severe 1 1% 1 1%
 Gastrointestinal
  None 128 81% 88 79%
  Mild 25 16% 20 18%
  Moderate 5 3% 4 4%
 Liver
  None 68 43% 48 43%
  Mild 40 25% 28 25%
  Moderate 27 17% 16 14%
  Severe 23 15% 20 18%
 Lung (evaluable in 154/158 patients)
  None 63 41% 45 41%
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Characteristics N=158 (%) N = 112 (%)
  Mild 74 48% 51 47%
  Moderate 15 10% 11 10%
  Severe 2 1% 2 2%
 Joint
  None 148 94% 105 94%
  Mild 9 6% 7 6%
  Moderate 1 — 0 —
Abbreviations: aGvHD = acute GvHD; BAFF = B-cell activating factor; cGvHD = chronic GvHD;; NIH-CC = National Institutes of Health 
Consensus Criteria. The characteristics did not differ between the subset of patients who were (n = 112) or were not (n = 46) evaluable for BAFF 
assessment (data not shown)—except for a higher prevalence (26% vs 11%, P = 0.03) of progressive-onset cGvHD and a shorter time interval 
between transplantation and cGvHD diagnosis (median 167 vs 274 days, P< 0.001) in the evaluable subset.
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Table 2
Univariable analysis of biologically relevant plasma soluble factors (evaluated in tertiles) 
and NRM
Soluble factor N HR at 4 years 95% CI P-value
BAFF ng/mL
 0–2.3 (low) 38 5.8 1.2–27 0.03
 >2.3–5.7 (intermediate)a 37 Reference
 >5.7–19.4 (high) 37 5.4 1.2–24 0.03
CXCL9 ng/mL
 0–10 (low) 39 2 0.7–6.7 0.25
 >10–41 (intermediate)b 36 Reference
 >41–171 (high) 35 2.3 0.7–7.7 0.2
Elafin ng/mL
 1.5–6.3 (low) 37 1.3 0.4–4.05 0.7
 >6.3–12.5 (intermediate)c 36 Reference
 >12.5–36.5 (high) 36 1.7 0.6–5.05 0.3
Abbreviations: BAFF = B-cell activating factor; CI = confidence interval; CXCL9 = chemokine C-X-C motif ligand 9; HR = hazard ratio; NRM = 
non-relapse mortality. Plasma concentration values of BAFF, CXCL9 and elafin were available in 112, 110 and 109 patients, respectively. 
Reference represents an hazard ratio (HR) of 1.0.
a
Intermediate vs high or low BAFF (HR = 0.2, 95% CI 0.04-0.8, P = 0.02).
b
Intermediate vs high or low CXCL9 (HR = 0.6, 95% CI 0.2-1.7, P = 0.4).
c
Intermediate vs high or low elafin (HR = 0.7, (95% CI 0.2-1.9, P = 0.4).
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Table 3
Multivariable analysis of predictors of NRM
Characteristic HR 95% CI P-value
Low BAFF levels 8.5 1.7–43 0.009
High BAFF levels 5.6 1.2–26 0.03
Maximum aGvHD severity 3 or 4 5.4 1.9–15 0.001
KPS ≤70% 2.6 1.02–6.5 0.045
Abbreviations: aGvHD =acute GvHD; BAFF = B-cell activating factor; CI = confidence interval; HR= hazard ratio; KPS=Karnofsky Performance 
Status; NRM = non-relapse mortality. Only patients (N =112) for whom plasma samples at the time of diagnosis of cGvHD were available were 
evaluable for multivariable analysis.
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